| Autor: |
Robert A. Uger, Jean C.Y. Wang, Liqing Jin, Nathan Mbong, Suzanne Trudel, James Koropatnick, Macarena Pampillo, Rene Figueredo, Saman Maleki Vareki, Eric L. Sievers, Emma Linderoth, Lisa D. Johnson, Stephane Viau, Tran Truong, Marilyse Charbonneau, Tapfuma Mutukura, Debbie Jin, Noel T. Vigo, Violetta House, Vivian Lee, Hui Chen, Vien Chai, Karen Dodge, Gloria H.Y. Lin, Xinli Pang, Mark Wong, Natasja Nielsen Viller, Penka S. Petrova |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.c.6526346.v1 |
| Popis: |
Purpose: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. CD47 is overexpressed in cancer cells and its expression is associated with poor clinical outcomes. TTI-621 (SIRPαFc) is a fully human recombinant fusion protein that blocks the CD47–SIRPα axis by binding to human CD47 and enhancing phagocytosis of malignant cells. Blockade of this inhibitory axis using TTI-621 has emerged as a promising therapeutic strategy to promote tumor cell eradication.Experimental Design: The ability of TTI-621 to promote macrophage-mediated phagocytosis of human tumor cells was assessed using both confocal microscopy and flow cytometry. In vivo antitumor efficacy was evaluated in xenograft and syngeneic models and the role of the Fc region in antitumor activity was evaluated using SIRPαFc constructs with different Fc tails.Results: TTI-621 enhanced macrophage-mediated phagocytosis of both hematologic and solid tumor cells, while sparing normal cells. In vivo, TTI-621 effectively controlled the growth of aggressive AML and B lymphoma xenografts and was efficacious in a syngeneic B lymphoma model. The IgG1 Fc tail of TTI-621 plays a critical role in its antitumor activity, presumably by engaging activating Fcγ receptors on macrophages. Finally, TTI-621 exhibits minimal binding to human erythrocytes, thereby differentiating it from CD47 blocking antibodies.Conclusions: These data indicate that TTI-621 is active across a broad range of human tumors. These results further establish CD47 as a critical regulator of innate immune surveillance and form the basis for clinical development of TTI-621 in multiple oncology indications. Clin Cancer Res; 23(4); 1068–79. ©2016 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
